ESMO Breast Cancer Congress 2022

By Caroline Helwick / May 2022 / ESMO Breast Cancer Congress 2022

Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer

In an updated analysis of the phase III MONALEESA-3 trial, which included postmenopausal patients with advanced/metastatic hormone receptor (HR)-positive, HER2-negative breast cancer, first-line treat...

Breast Cancer

Immunotherapy

By Caroline Helwick / May 2022 / ESMO Breast Cancer Congress 2022

TUXEDO-1: Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases

In the single-center phase II TUXEDO-1 trial of patients with advanced HER2-positive breast cancer, fam-trastuzumab-deruxtecan-nxki (T-DXd) showed efficacy in patients with active brain metastases, yi...

ESMO Breast Cancer Congress 2022

Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer

TUXEDO-1: Efficacy of T-DXd for Patients With HER2-Positive Breast Cancer and Active Brain Metastases

Patients With NSCLC Brain Metastases Undergoing Neurosurgical Resection Comparison of Treatment Regimens

Segmentectomy vs Lobectomy in Small-Sized Peripheral NSCLC

Consolidation Durvalumab Alone or Combined With Oleclumab or Monalizumab for Unresectable Stage III NSCLC

Beyond Immunotherapy: New Targeted Agents for Advanced NSCLC

Drug Developers Share Thoughts on the Oncology Pipeline and the Changes in Clinical Trials